ANAndrzej Nowakowski

Andrzej Nowakowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrzej Nowakowski has a total of 320 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Primary Human Papillomavirus Screening Versus Cytology for Detection of Cervical Intraepithelial Neoplasia Grade 2 or Higher in Poland: a Parallel-Group, Randomized Controlled Trial

    by Andrzej Nowakowski, Anna Macios, Patrycja Glinska, Aneta Chmielewska, Beata Janik, Ilona JęDrzejewska, Alicja Klimiuk, Ewa Chmielik, Piotr Bobkiewicz, Ewa Kapuśniak, et al.


  • Open Access

    Lack of consensus in calculation of interval cancer rates for cervical cancer screening

    by Patricia Fitzpatrick, Therese Mooney, Yvonne Williams, Caroline Mason Mohan, Jesper Bonde, Julia Gao, Andrzej Nowakowski, Annemie Haelens, Urska Ivanus, Maiju Pankakoski, et al.

    Introduction: In 2018, nondisclosure of results of retrospective audits of cytology in interval cancers precipitated a crisis in the Irish national cervical screening programme. In response, an Expert Reference Group was convened which recommended a collaborative approach to the development of a new key performance indicator, the interval cancer rate. The Expert Reference Group also recommended that the Irish programme should collaborate with international colleagues to reach consensus on (i) the definition of an interval cervical cancer, (ii) the methodology to calculate the interval cancer rate, and (iii) benchmarking with other international programs. This study was undertaken to determine if a consensus regarding the definition of an interval cervical cancer and the calculation of an interval cancer rate exists.Material and Methods: A web‐based questionnaire was sent to 18 population‐based cervical screening programs. Inclusion criteria involved (1) a national or regional population‐based cervical screening prograe; (2) a country or region with a population ≥population of Ireland; (3) programs located in Europe, Australia, or Canada; (4) programs that had responded to a previously published international survey on the disclosure of retrospective cytology reviews in cervical cancer cases.Results: The response rate was nine out of 18. Of nine respondents, six had an agreed definition of interval cervical cancer, and four of these calculated an interval cancer rate. Three programs neither calculated interval cancer rates nor had any guidelines related to this. Of the six with an agreed definition, all respondents defined the numerator as invasive cancers in the screening age group, with four including microinvasive disease. Respondents included cancers diagnosed 3–5 years after the last screening test had been taken. Three respondents also included cancers diagnosed in women up to 3.5 years after they exited the screening program. Countries use different denominators, including (i) per women years, (ii) per number of screens, and (iii) per total cancers in screened population.Conclusions: There is variation in the parameters used in interval cancer rate calculation. To allow benchmarking of cervical screening program performance, there is a need for consensus on a standardized method of interval cancer definition and interval cancer rate calculation.

  • Open Access

    Cervical microbiota dysbiosis associated with high-risk Human Papillomavirus infection

    by Natalia Zeber-Lubecka, Maria Kulecka, Michalina Dabrowska, Katarzyna Baginska-Drabiuk, Maria Glowienka-Stodolak, Andrzej Nowakowski, Aneta Slabuszewska-Jozwiak, Bożena Bednorz, Ilona Jędrzejewska, Magdalena Piasecka, et al.

    High-risk Human Papillomavirus (HR-HPV) genotypes, specifically HPV16 and HPV18, pose a significant risk for the development of cervical intraepithelial neoplasia and cervical cancer. In the multifaceted cervical microenvironment, consisting of immune cells and diverse microbiota, Lactobacillus emerges as a pivotal factor, wielding significant influence in both stabilizing and disrupting the microbiome of the reproductive tract. To analyze the distinction between the cervical microbiota and Lactobacillus-dominant/non-dominant status of HR-HPV and non-infected healthy women, sixty-nine cervical swab samples were analyzed, included 44 with HR-HPV infection and healthy controls. All samples were recruited from Human Papillomavirus-based cervical cancer screening program and subjected to 16s rRNA sequencing analysis. Alpha and beta diversity analyses reveal no significant differences in the cervical microbiota of HR-HPV-infected women, including 16 and 18 HPV genotypes, and those with squamous intraepithelial lesion (SIL), compared to a control group. In this study we identified significantly lower abundance of Lactobacillus mucosae in women with HR-HPV infection compared to the control group. Furthermore, changes in bacterial diversity were noted in Lactobacillus non-dominant (LND) samples compared to Lactobacillus-dominant (LD) in both HR-HPV-infected and control groups. LND samples in HR-HPV-infected women exhibited a cervical dysbiotic state, characterized by Lactobacillus deficiency. In turn, the LD HR-HPV group showed an overrepresentation of Lactobacillus helveticus. In summary, our study highlighted the distinctive roles of L. mucosae and L. helveticus in HR-HPV infections, signaling a need for further research to demonstrate potential clinical implications of cervical microbiota dysbiosis.


  • Open Access

    HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)—study protocol of a randomised healthcare policy trial

    by Patrycja Glinska, Katarzyna Komerska, Beata Janik, Julia Olkowicz, Ilona Jedrzejewska, Anna Macios, Paulina Wieszczy, Michal F. Kaminski, Marc Arbyn, Andrzej Nowakowski

    Background: An Organised Cervical Cancer Screening Programme (OCCSP) was started in Poland in 2006/2007. Each woman aged 25 to 59 is eligible for a free Pap test every 3 years in OCCSP. Despite implementation of the OCCSP, the age-standardised cervical cancer (CC) incidence and mortality rates in 2019 were 7.3/100 000 and 3.9/100 000 respectively and were still higher than those in Western European countries with well-organised screening programmes. Apart from low coverage of the OCCSP, suboptimal performance of the screening test (conventional cytology) may be partially responsible for this situation. Several countries have already incorporated high risk Human Papillomavirus (hrHPV) testing in CC screening as a more sensitive tool reducing the risk of missing precancerous lesions and allowing for extension of screening intervals. The European Guidelines for Quality Assurance in Cervical Cancer Screening recommend pilot evaluation of a new screening test in country-specific conditions before its implementation. Methods: The HIPPO project (HPV testing In Polish POpulation-based cervical cancer screening program) is a randomised health services study nested in the OCCSP in Poland. The project will randomise 33 000 women aged 30–59 years to cytology or hrHPV testing (ratio: 1:1) with age stratification. In the cytology arm women with repeated Atypical Squamous Cells of Undetermined Significance (ASC-US) or ≥ Low–Grade Squamous Intraepithelial Lesions (LSIL) are referred for colposcopy. In the other arm, hrHPV ( +) women with ≥ ASC-US reflex Liquid-Based Cytology (LBC) are referred for colposcopy. Primary endpoints include detection rates of histologically confirmed high grade intraepithelial lesions or worse (CIN2 +) in each arm. Discussion: This pilot randomised healthcare study nested in the OCCSP in Poland will assess and compare the performance of hrHPV testing to current standard—cytology in order to make decisions on implementation of HPV-based screening in the country. Trial registration: This randomised healthcare service study was prospectively registered at https://clinicaltrials.gov/ (identifier: NCT04111835, protocol ID 28/2019) on 19th of September 2019.


  • Recommendations of the Polish Society of Gynaecologists and Obstetricians, Polish Paediatric Society, Polish Society of Family Medicine, Polish Society of Vaccinology, Polish Society of Oncological Gynaecology and Polish Society of Colposcopy and Pathophysiology of the Uterine Cervix on prophylactic vaccinations against infections with human papillomaviruses in Poland

    by Andrzej Nowakowski, Robert Jach, Leszek Szenborn, Mariusz Bidzinski, Teresa Jackowska, Jan Kotarski, Agnieszka Mastalerz-Migas, Aneta Nitsch-Osuch, Jaroslaw Pinkas, Wlodzimierz Sawicki, et al.

    Several hundred million people are infected with genital genotypes of the human papillomavirus (HPV) annually in the world. The infections transmitted mainly through sexual routes are usually asymptomatic, but can lead to the development of cervical, vulvar, vaginal, anal, penile cancers, some head and neck cancers and genital warts (condylomas). The fraction HPV-related cancers range from nearly 100% in the case of cervical cancer to several/over a dozen percent in the case of other cancers and diseases. There are no effective drugs against HPV, but prophylactic HPV vaccines are available free of charge in immunization programmes in many countries around the world. In Poland, HPV vaccinations have so far been executed out on the pocket or in free-of-charge, local-governmental prevention programs, but the vaccination coverage of the target population does not exceed 10%. From November 2021, one of the vaccines is available with a 50% reimbursement, work is underway to reimburse the next ones, and the National Oncology Strategy assumes the implementation of the HPV immunization programmes and vaccination of 60% of the teen population by 2028. Three prophylactic HPV vaccines are registered. All of them are safe and their effectiveness in the prevention of diseases caused by vaccine genotypes reaches almost 100%, provided that full post-vaccination immunity is obtained before the contact with the virus. Girls aged 11-13 are the priority target cohort for HPV vaccination in Poland. The implementation of routine, free-of-charge HPV immunization in the Preventive Immunization Program (PIP) for all adolescents should be pursued. Persons over the age of 13 may also benefit from HPV vaccination and should be vaccinated according to product specifications. In addition to free access under the PIP, the key element for the success of the implementation of HPV vaccinations in Poland will be the education of medical personnel and parents of adolescents to be vaccinated. Several hundred million people are infected with genital genotypes of the human papillomavirus (HPV) annually in the world. The infections transmitted mainly through sexual routes are usually asymptomatic, but can lead to the development of cervical, vulvar, vaginal, anal, penile cancers, some head and neck cancers and genital warts (condylomas). The fraction HPV-related cancers range from nearly 100% in the case of cervical cancer to several/over a dozen percent in the case of other cancers and diseases. There are no effective drugs against HPV, but prophylactic HPV vaccines are available free of charge in immunization programmes in many countries around the world. In Poland, HPV vaccinations have so far been executed out on the pocket or in free-of-charge, local-governmental prevention programs, but the vaccination coverage of the target population does not exceed 10%. From November 2021, one of the vaccines is available with a 50% reimbursement, work is underway to reimburse the next ones, and the National Oncology Strategy assumes the implementation of the HPV immunization programmes and vaccination of 60% of the teen population by 2028. Three prophylactic HPV vaccines are registered. All of them are safe and their effectiveness in the prevention of diseases caused by vaccine genotypes reaches almost 100%, provided that full post-vaccination immunity is obtained before the contact with the virus. Girls aged 11-13 are the priority target cohort for HPV vaccination in Poland. The implementation of routine, free-of-charge HPV immunization in the Preventive Immunization Program (PIP) for all adolescents should be pursued. Persons over the age of 13 may also benefit from HPV vaccination and should be vaccinated according to product specifications. In addition to free access under the PIP, the key element for the success of the implementation of HPV vaccinations in Poland will be the education of medical personnel and parents of adolescents to be vaccinated.


  • Open Access

    Interlaboratory agreement in assessment of gynaecological cytology in Cervical Cancer Screening Programme in Poland – a pilot evaluation

    by Kinga Zalewska-Otwinowska, Anna Macios, Katarzyna Komerska, Małgorzata Rekosz, Andrzej Nowakowski

    In our pilot study we have aimed to assess interlaboratory variability of cytological diagnoses in selected laboratories participating in the Polish Cervical Cancer Screening Programme (CCSP) to establish grounds for certification system for cytodiagnosticians and to monitor the quality of...


  • Open Access

    A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention

    by Andrzej Nowakowski, Marc Arbyn, Maryla H. Turkot, Paulina Wieszczy, Kinga Miłosz, Michał F. Kamiński, Joanna Didkowska, Mariusz Bidziński, Włodzimierz Olszewski, Mirosław Wielgoś, et al.

    In Poland, cervical cancer incidence and mortality still remain considerably higher than in Western European countries or North America. Recent data indicate decreasing trends in women younger than 60 years and stable trends in older women. In this article, we identified obstacles in primary and secondary prevention of cervical cancer in Poland. We analysed local legislation, management structure and organization of cervical cancer prevention in Poland and reviewed solutions available and implemented in other European countries. The main weaknesses include: (i) very low coverage of organized screening; concurrent unregistered opportunistic screening with unknown coverage and high test consumption (ii) suboptimal quality assurance in organized screening and no external quality assurance in opportunistic screening (iii) very low coverage of human papillomavirus vaccination that is not centrally reimbursed (iv) absence of pilot evaluation of (a) interventions that may improve population coverage and (b) performance of new preventive strategies. The proposed solutions are multifaceted and involve: (i) legislative and organizational regulation of cervical cancer screening aimed at comprehensive registration of procedures, data access and quality assurance (ii) pilot testing and implementation of new ways to increase coverage of cervical cancer screening, in particular among older women (iii) pilot evaluation with possible introduction of human papillomavirus-based screening and (iv) inclusion of human papillomavirus vaccination into the reimbursed national immunization program.


  • MMP-2 mRNA Expression in Ovarian Cancer Tissues Predicts Patients' Response to Platinum-Taxane Chemotherapy

    by Witold Jeleniewicz, Marek Cybulski, Andrzej Nowakowski, Agnieszka Stenzel-Bembenek, Małgorzata Guz, Barbara Marzec-Kotarska, Jan Kotarski, Andrzej Stepulak

    Background/Aim: Ovarian cancer is the most frequent cause of death in women among gynecological cancers in Poland. MMP-2 and MMP-9 are frequently dysregulated in cancers and they are considered as potential biomarkers. Our goal was to assess the associations between MMP-2 and MMP-9 mRNA expression, clinicopathological parameters and patients' response to chemotherapy. Materials and Methods: We evaluated MMP-2 and MMP-9 mRNA expression in epithelial ovarian cancer (EOC) tissues from 44 untreated patients, four ovarian cancer cell lines, and human skin fibroblasts (HSF). The expression of both MMPs was estimated using qPCR. Results: MMP-2 expression was significantly higher (p=0.020) in EOCs sensitive to chemotherapy compared to resistant and refractory tumors. The highest MMP-2 expression was found in HSF and MMP-9 expression was the highest in EOCs (p<0.001). The expression of neither MMP was significantly associated with patients' overall survival (OS). Conclusion: MMP-2 may be engaged in early stages of ovarian carcinogenesis. MMP-2 expression in EOCs may discriminate patients with a favorable response to first line chemotherapy.


  • External audit of providers of the Cervical Cancer Prevention Programme in Poland in 2016/2017

    by Maryla Turkot, Dagmara Mokwa, Paulina Wieszczy, Katarzyna Spych, Natalia Kurowska, Andrzej Nowakowski, Michał F. Kamiński

    Introduction. The Cervical Cancer (CC) Prevention Programme includes 3 phases: basic (Pap smear collection), diagnostic (Pap smear evaluation) and in-depth (colposcopy/biopsy in case of abnormal smear test findings). The Programme service providers are subject to an external audit and this publication’s objective is to analyse its results from 2016 and the first half of 2017. Materials and methods. The audit of the Programme performance in the period 01.01.2016–30.06.2017 was carried out by external auditors by way of personal visits to the offices of the service providers and by way of direct data retrieval. The audit covered 12% (198) of the basic phase, 100% (66) of the diagnostic phase and 100% (62) of the in-depth phase facilities. The Polish National Health Fund (NHF) did not make available the routinely collected data for the purpose of audit. Audit data collected in the developed protocols were analysed. Results. The number of Pap smears (2,028,988) and the number of colposcopies (13,636) outside the Programme was, respectively, more than two and three times higher than in the Programme (cytology — 801,640, colposcopy — 3929). The performance of the procedures (Programme vs outside the Programme) was highly variable depending on the provider. The percentage of Pap smears unsuitable for evaluation did not differ significantly between gynaecologists and midwives. All audited cytological laboratories carried out rescreening of samples. Biopsy was not performed in 11% (2016) and 15% (2017) of colposcopy laboratories. Inaccuracies were found in 19% (61) of the audit protocols. Discussion. Significantly higher number of procedures performed outside the Programme results from lower renu­meration of procedures within the Programme. Variable provider's preferences in the mode of procedures execution indicates that with the use of appropriate organisational solutions it would be possible to reduce opportunistic screening, which is of unknown quality. The quality of Pap smear sample collection in the case of gynaecologists and midwives is the same, but the number of primary care provider (PCP) facilities where midwives collect smears is very limited. The inaccuracies noted in the audit protocols indicate that the lack of access to data collected by the National Health Fund decreased the quality of the audit carried out and the reliability of the data obtained. Conclusions. Restoring full access to data collected by the NHF is crucial for the Programme audit quality. Measures should be implemented to reduce opportunistic screening and shift the stream of tests to the Programme (both at the basic and at the in-depth phase), and to increase the availability of tests in PCP facilities through training for midwives. Introduction. The Cervical Cancer (CC) Prevention Programme includes 3 phases: basic (Pap smear collection), diagnostic (Pap smear evaluation) and in-depth (colposcopy/biopsy in case of abnormal smear test findings). The Programme service providers are subject to an external audit and this publication’s objective is to analyse its results from 2016 and the first half of 2017. Materials and methods. The audit of the Programme performance in the period 01.01.2016–30.06.2017 was carried out by external auditors by way of personal visits to the offices of the service providers and by way of direct data retrieval. The audit covered 12% (198) of the basic phase, 100% (66) of the diagnostic phase and 100% (62) of the in-depth phase facilities. The Polish National Health Fund (NHF) did not make available the routinely collected data for the purpose of audit. Audit data collected in the developed protocols were analysed. Results. The number of Pap smears (2,028,988) and the number of colposcopies (13,636) outside the Programme was, respectively, more than two and three times higher than in the Programme (cytology — 801,640, colposcopy — 3929). The performance of the procedures (Programme vs outside the Programme) was highly variable depending on the provider. The percentage of Pap smears unsuitable for evaluation did not differ significantly between gynaecologists and midwives. All audited cytological laboratories carried out rescreening of samples. Biopsy was not performed in 11% (2016) and 15% (2017) of colposcopy laboratories. Inaccuracies were found in 19% (61) of the audit protocols. Discussion. Significantly higher number of procedures performed outside the Programme results from lower renu­meration of procedures within the Programme. Variable provider's preferences in the mode of procedures execution indicates that with the use of appropriate organisational solutions it would be possible to reduce opportunistic screening, which is of unknown quality. The quality of Pap smear sample collection in the case of gynaecologists and midwives is the same, but the number of primary care provider (PCP) facilities where midwives collect smears is very limited. The inaccuracies noted in the audit protocols indicate that the lack of access to data collected by the National Health Fund decreased the quality of the audit carried out and the reliability of the data obtained. Conclusions. Restoring full access to data collected by the NHF is crucial for the Programme audit quality. Measures should be implemented to reduce opportunistic screening and shift the stream of tests to the Programme (both at the basic and at the in-depth phase), and to increase the availability of tests in PCP facilities through training for midwives.